Welcome to our dedicated page for PetVivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PetVivo Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PetVivo Holdings's regulatory disclosures and financial reporting.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.
PetVivo Holdings (PETV) reported an insider transaction on Form 4. Chief Financial Officer Garry Lowenthal received 75,000 shares of restricted common stock on 10/23/2025 at a reported price of $1.27 per share. The grant was issued to a corporation owned by him as compensation for past performance. After this grant, he beneficially owns 667,967 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider transaction on a Form 4. CEO and Director John Lai acquired 75,000 shares of common stock on 10/23/2025 at $1.27 per share. The filing states the shares were a grant of restricted common stock to a corporation he owns, as compensation for past performance by converting a past accrued bonus into common stock.
After the transaction, Lai beneficially owned 2,095,710 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider equity award. Director Diane Levitan acquired 12,500 shares of restricted common stock at $1.28 on 10/10/2025. The award is part of an aggregate annual grant of 50,000 shares for Board service, vesting in four equal installments of 12,500 at the beginning of each quarter.
Following this transaction, Levitan beneficially owns 56,489 shares, held directly.
PetVivo Holdings (PETV) director reported multiple stock grants. On 10/01/2025, the director acquired 14,935 shares of restricted common stock at $1.19 as compensation for prior consulting services. On 10/10/2025, additional restricted stock grants were recorded: 12,500 shares at $1.28 for quarterly Board service vesting, 50,000 shares at $1.28 tied to a warrant exercise with a $25,000 payment to the company, and 100,000 shares at $1.28 tied to a warrant exercise with a $50,000 payment to the company. Following these transactions, beneficial ownership stood at 311,807 shares, held directly.
PetVivo Holdings (PETV) reported a Form 4 for director Robert Rudelius. On 10/10/2025, he acquired 12,500 shares of common stock at $1.28 as part of an annual 50,000 restricted-share board compensation grant that vests in four equal quarterly installments. Following the transaction, he beneficially owned 314,369 shares directly and 21,000 shares indirectly via a corporation.
PetVivo Holdings (PETV) reported a Form 4 showing Director Joseph Jasper acquired 12,500 restricted common shares at $1.28 on 10/10/2025. The transaction reflects the first quarterly vesting from an annual board compensation grant of 50,000 shares, vesting in four equal installments of 12,500 each.
Following the transaction, Jasper beneficially owned 100,159 shares directly, plus 2,000 shares indirectly held by his spouse.
PetVivo Holdings (PETV) disclosed a Form 4 for a director on 10/10/2025, reporting the acquisition of 12,500 shares of common stock at $1.28 per share. Following the transaction, the director beneficially owns 73,661 shares directly.
The filing notes this is part of an aggregate annual grant of 50,000 restricted shares for Board service, vesting in four equal installments of 12,500 shares at the beginning of each quarter.
PetVivo Holdings, Inc. reporting person John Lai, who serves as Chief Executive Officer and a director, reported a non‑derivative acquisition on 09/18/2025. The filing shows a grant of 84,375 shares of common stock at a price of $0.76 to a corporation owned by the reporting person as compensation for past performance, reflecting conversion of a past accrued bonus into common stock. Following the transaction, the reporting person (indirectly) beneficially owned 2,020,710 shares. The Form 4 is signed by John Lai on 09/22/2025. The filing indicates the award was issued as compensation rather than a market purchase.
Garry Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., received a grant of restricted common stock on 09/18/2025 as compensation for past performance. The grant consisted of 79,375 shares at a stated price of $0.76 and was issued to a corporation owned by Mr. Lowenthal. After the reported transaction, the reporting persons indirect beneficial ownership totaled 592,967 shares. The Form 4 indicates this was a non-derivative award recorded as an acquisition and identifies the grant as compensation rather than a market purchase.